Status:
UNKNOWN
Rosuvastatin Effect on Telomere-telomerase System in ACS
Lead Sponsor:
Xiao-dong Zhuang
Collaborating Sponsors:
Sun Yat-sen University
Conditions:
Telomere Shortening
Telomere Length, Mean Leukocyte
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Coronary heart disease (CHD) is one of the diseases characterised by biological aging as one of the important risk factors in several epidemiological studies. The mean telomere length and telomerase a...
Detailed Description
Coronary heart disease (CHD) is identified as one of the diseases characterised by biological aging as one of the important risk factors in several epidemiological studies. Premature biological aging ...
Eligibility Criteria
Inclusion
- Subjects with ACS, planing for PCI treatment
- Male or females who are 18-80years of age
- No current or previous statin therapy
- No current indication for statin therapy (Coronary artery disease; hypercholesterolemia, renal dysfunction)
- Subjects who have given their signed consent to participate in the study
Exclusion
- Patient \< 18 or \> 80 years
- Renal dysfunction
- Hyperlipidemia
- Active myositis
- All forms of liver disease
- Pregnancy
- Breastfeeding
- Patients being treated with other type statin
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2016
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT02299245
Start Date
October 1 2014
End Date
November 1 2016
Last Update
July 14 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.